Clinical trials
catalyst calendar across sponsors →Studies where ATNM is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
6 interventional
Held by 5 tracked-famous managers (MILLENNIUM MANAGEMENT LLC, RENAISSANCE TECHNOLOGIES LLC, TWO SIGMA INVESTMENTS, LP, Qube Research & Technologies Ltd, SUSQUEHANNA INTERNATIONAL GROUP, LLP) · FINRA short interest 10.3 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AMLNCT07157514Overall Survival (OS) -Phase 3Randomized · Open-label · Treatment | Phase 2/3 | Not yet recruiting | Drug: 131I-apamistamab, Fludarabine, Cyclophosphamide · Radiation: Total Body Irradiation (TBI) · Biological: Allogeneic Hematopoietic Stem Cell Transplant (HSCT) | Acute Leukemia, Myeloid Leukemia, Acute Myelogenous Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse, Myelogenous Leukemia, Myelogenous Leukemia, Acute, Myelogenous Leukemia in Relapse, Transplant-Related Disorder, Allogeneic Disease, Refractory AML | 306 | Feb 2029 | ≤ 924 d | 2025-09-10 |
| Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid LeukemiaNCT02665065Durable Complete Remission (dCR)Randomized · Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: Iomab-B, Conventional Care · Procedure: HCT | Acute Myeloid Leukemia, Leukemia, Acute Myeloid, Myeloid Leukemia, Acute, Leukemia, Myeloid, Acute, Acute Myelogenous Leukemia, Leukemia, Acute Myelogenous, Myelogenous Leukemia, Acute, AML, Bone Marrow Transplant | 153 | Jun 2022actual | — | 2023-07-19 |
| Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML PatientsNCT03932318Phase I: Maximum Tolerated Dose (MTD) of Lintuzumab-Ac225Open-label · Treatment | Phase 1/2 | Withdrawnsponsor's stated reason: study postponed | Biological: Lintuzumab-Ac225 · Drug: Venetoclax, Azacitidine | Acute Myeloid Leukemia, Relapsed Adult AML | 0 | Dec 2023 | — | 2023-07-20 |
| Venetoclax and Lintuzumab-Ac225 in AML PatientsNCT03867682Phase I: Maximum Tolerated Dose (MTD) of Lintuzumab-Ac225Open-label · Treatment | Phase 1/2 | Unknown status | Biological: Lintuzumab-Ac225 · Drug: Venetoclax, Spironolactone | Acute Myeloid Leukemia, Relapsed Adult AML | 38 | Nov 2023 | — | 2023-08-04 |
| A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple MyelomaNCT02998047Maximum Tolerated dose of Lintuzumab-AC225Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Poor recruitment | Drug: Lintuzumab AC 225 | Refractory Multiple Myeloma | 2 | May 2020actual | — | 2022-03-08 |
| Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) PatientsNCT02575963Phase I: Maximum Tolerated Dose (MTD) of Lintuzumab-Ac225Open-label · Treatment | Phase 1/2 | Completed | Drug: Cytarabine (Phase 1 only), Furosemide (Phase 1 only), Spironolactone · Biological: Lintuzumab-Ac225 | AML | 40 | Nov 2018actual | — | 2023-07-20 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19